Berbis P, Bun H, Al Mallah N R, Durand A, Rognin C, Geiger J M, Privat Y
Clinique Dermatologique, Hotel-Dieu, Marseille, France.
Dermatologica. 1988;177(4):244-6.
In order to study the elimination of Ro 10-1670 (acitretin) and Ro 13-7652, its 13-cis-isomeric metabolite after chronic administration, determination of the residual plasma concentrations of these two compounds were assayed in 9 patients in a range of 22-30 days following cessation of a 2- to 7.5-month course with daily oral doses of 10-50 mg of acitretin. A highly sensitive HPLC method was used (2 ng/ml). Residual plasma concentrations of Ro 10-1670 were below the quantification limit in all cases. Residual plasma concentrations of Ro 13-7652 were below the quantification limit in 7 cases and respectively of 3 and 4 ng/ml in the other 2 cases. These data appear to confirm the absence of storage of acitretin even after an extended course of therapy.
为研究长期给药后阿维A(Ro 10-1670)及其13-顺式异构体代谢产物Ro 13-7652的消除情况,在9例患者中,于每日口服10-50mg阿维A进行2至7.5个月疗程停药后的22至30天内,测定了这两种化合物的血浆残留浓度。采用了高灵敏度的HPLC方法(2ng/ml)。所有病例中Ro 10-1670的血浆残留浓度均低于定量限。7例患者中Ro 13-7652的血浆残留浓度低于定量限,另外2例患者的残留浓度分别为3ng/ml和4ng/ml。这些数据似乎证实,即使经过延长疗程的治疗,阿维A也不会蓄积。